Medications

First biosimilar approved to treat multiple sclerosis

The U.S. Food and Drug Administration approved Tyruko (natalizumab-sztn), the first biosimilar to Tysabri (natalizumab) injection, for the treatment of relapsing forms of multiple sclerosis, the agency announced Thursday.

Diseases, Conditions, Syndromes

New guidance for infection prevention in acute care settings

Five medical societies have published a set of recommendations for operationalizing strategies for infection prevention in acute care settings that account for conditions within the facility, including the culture and communications ...

page 4 from 40